Core Viewpoint - Smith & Nephew (SNN) is currently identified as a strong value stock, exhibiting favorable valuation metrics compared to its industry peers [4][5][6][7]. Valuation Metrics - SNN has a P/E ratio of 13.95, significantly lower than the industry average of 20.92 [4]. - The stock's PEG ratio stands at 0.84, compared to the industry's average PEG of 1.86, indicating better value relative to expected earnings growth [5]. - SNN's P/B ratio is 2.43, which is also lower than the industry average of 5.14, suggesting a solid market value compared to its book value [6]. Performance Insights - Over the past year, SNN's Forward P/E has fluctuated between 11.60 and 16.17, with a median of 13.82 [4]. - The PEG ratio for SNN has ranged from 0.67 to 1.47, with a median of 1.12, indicating potential undervaluation [5]. - The P/B ratio has varied between 1.98 and 2.66, with a median of 2.36, reinforcing the perception of SNN as undervalued [6]. Investment Outlook - Given the strength of its earnings outlook and favorable valuation metrics, SNN is positioned as one of the market's strongest value stocks [7].

Core Viewpoint - Smith+Nephew has launched the TRIGEN MAX Tibia Nailing System, which features side-specific nails and variable angle locking technology, aimed at improving fracture fixation for tibia fractures [1][4][5]. Product Features - The TRIGEN MAX Tibia Nailing System offers trauma surgeons the option of side-specific nails for optimized screw trajectories, enhancing fragment fixation and reducing soft tissue irritation [1][5]. - The system includes a two-piece modular drop system for better visualization and ancillary instrument use, a 12.5mm channel reamer designed to protect soft tissue, and 5.0mm Lag Screws that streamline the workflow by compressing fractures in one insertion step [6]. Market Position - The TRIGEN MAX Tibia Nailing System is positioned as the next flagship product for Smith+Nephew, building on over two decades of proven performance in the TRIGEN Nails family [4]. - The system is currently available only in the United States, indicating a focused market entry strategy [7]. Company Overview - Smith+Nephew is a global medical technology company focused on the repair, regeneration, and replacement of soft and hard tissue, with annual sales of $5.8 billion in 2024 [9]. - The company operates in approximately 100 countries and is a constituent of the FTSE100 [9].

Core Insights - Smith + Nephew (SNN) has formed a strategic partnership with Standard Health to establish the UK's first dedicated Orthopaedic Ambulatory Surgery Centre (ASC) in Poole, Dorset, aimed at transforming outpatient orthopedic care [1][4][6] - The collaboration combines SNN's innovative surgical solutions with Standard Health's clinical expertise to enhance patient outcomes and reduce surgical wait times [2][4] - SNN's market capitalization stands at $12.52 billion, with projected fiscal 2025 revenues of $6.12 billion, indicating a growth of 10.3% from fiscal 2023 [5] Company Developments - The new ASC will focus on minimally invasive procedures, including rotator cuff repairs, ACL reconstructions, and joint replacements, catering to both NHS and private patients [1][7] - SNN is positioned to capitalize on the growing trend towards outpatient orthopedic procedures, enhancing its presence in the ASC market and driving adoption of its surgical technologies [4][9] - Standard Health plans to expand to 20 ASC sites across the UK by 2030, providing SNN with scalable opportunities to deepen its market presence [6][9] Industry Trends - The global ambulatory surgery centers market is projected to grow from $134.9 billion in 2023 to $205.5 billion by 2030, with a CAGR of 6.2% from 2024 to 2030, driven by a shift of surgical procedures from hospitals to ASCs [10] - The ASC model has shown greater procedural efficiency and patient satisfaction, making it an attractive alternative to traditional hospital settings [8][10] - With over 850,000 patients awaiting orthopedic surgeries in the UK, the NHS is increasingly relying on independent providers to alleviate backlogs, indicating a strong demand for SNN's services [9]

Core Viewpoint - Smith+Nephew has announced a strategic partnership with Standard Health to develop the first Orthopaedic Ambulatory Surgery Centre in the UK, aimed at improving access to advanced joint repair and replacement technologies for patients [1][2]. Company Overview - Smith+Nephew is a global medical technology company focused on the repair, regeneration, and replacement of soft and hard tissue, with annual sales of $5.8 billion in 2024 [9]. - Standard Health specializes in orthopaedic care and has provided NHS services since 2012, with plans for nationwide expansion [10]. Partnership Details - The new centre in Poole, Dorset, will cater to both NHS and private patients, offering procedures such as rotator cuff repair and knee replacements, and is expected to open in 2025 [1][3]. - Standard Health plans to open an additional 10 sites in the UK over the next three years, totaling 20 by 2030 [2]. Operational Model - The centre will adopt the Ambulatory Surgery Center (ASC) model from the US, which has proven benefits including increased procedural efficiency and high patient satisfaction rates [3][6]. - In the US, ASCs account for over 50% of all outpatient surgical procedures, with more than 6,000 facilities currently operating [3]. Market Demand - There are over 850,000 individuals waiting for orthopaedic surgery in the UK, highlighting the need for independent providers to meet this demand [3]. - The partnership aims to address the long wait times for procedures in the UK, providing a sustainable model for care [4]. Expected Benefits - The ASC model is associated with a 92% patient satisfaction rate and can reduce costs of joint replacements by 40% compared to hospital-based surgeries [6]. - The collaboration is expected to enhance the quality of care for patients and provide value for NHS commissioners [4].

Core Insights - Smith+Nephew has introduced a new medial stabilized insert for its LEGION Total Knee System, reflecting a significant shift in knee arthroplasty trends from Posterior Stabilized designs to more bone-conservative Cruciate Retaining designs, with medial stabilized inserts growing from 4% in 2018 to 32% in 2023 [1][2][4] Company Overview - Smith+Nephew is a global medical technology company focused on the repair, regeneration, and replacement of soft and hard tissue, with a mission to restore people's bodies and self-belief through innovative technologies [7][8] - The company generated annual sales of $5.8 billion in 2024 and operates in around 100 countries, being a constituent of the FTSE100 [8] Product Development - The new medial stabilized insert is designed to enhance stability with a larger anterior medial lip and kinematics that mimic the natural knee, aiming for greater efficiency and shorter operating times [1][2] - The LEGION Medial Stabilized TKS is positioned as a solution that aligns with personalized care principles, integrating advanced technologies and maintaining a strong clinical legacy [2][5] Market Trends - There is a growing demand for porous and kinematically advanced knee solutions, with the LEGION Medial Stabilized TKS expected to meet the evolving needs of patients and surgeons [5] - The product will be available in the US on a limited basis, with a full commercial release planned for 2025 and an introduction in Canada in 2026 [5]

Core Viewpoint - Smith+Nephew has been awarded a 10-year contract worth up to $75 million by the U.S. Department of Defense to provide its RENASYS TOUCH Negative Pressure Wound Therapy Systems, highlighting the company's commitment to supporting military medical needs [1][9]. Group 1: Product and Technology - The RENASYS TOUCH NPWT System is noted for its clinical efficacy and operational features such as portability, intuitive interface, and customizable therapy modes, which enhance individualized patient care [2]. - This system is designed to assist military medical providers in various scenarios, including prolonged casualty care and aeromedical transport, ensuring effective treatment in military settings [2]. Group 2: Strategic Partnerships - In 2024, Smith+Nephew entered into a Master Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research to innovate wound and burn care across the military care continuum [6]. Group 3: Historical Context and Commitment - Smith+Nephew has a historical legacy of supporting military medical needs, dating back to World War I, and continues to evolve its offerings to meet the demands of both civilian and military healthcare [7]. - The company emphasizes its ongoing commitment to innovation in wound care through an extensive Advanced Wound Management portfolio aimed at addressing complex clinical needs [7].

Core Insights - Smith+Nephew has been awarded a 10-year contract worth up to $75 million by the U.S. Department of Defense to provide its RENASYS TOUCH Negative Pressure Wound Therapy Systems [1][8] - The RENASYS TOUCH NPWT System is designed for clinical efficacy and operational fitness, including portability and an intuitive interface, allowing for individualized patient care [2][5] - The system will support military medical providers in various care settings, including prolonged casualty care and aeromedical transport [2][5] Group 1 - The RENASYS TOUCH NPWT System is manufactured in the United States, emphasizing local production [2] - The system is intended to simplify negative pressure wound therapy for military applications, addressing the complexities of future conflicts [5] - Smith+Nephew has a historical commitment to military medical needs, dating back to World War I, and continues to innovate in wound care [6][10] Group 2 - In 2024, Smith+Nephew entered into a Master Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research to enhance wound and burn care in military settings [6] - The company generated annual sales of $5.8 billion in 2024 and operates in around 100 countries, indicating a strong global presence [11]

Core Insights - Smith+Nephew's CARTIHEAL AGILI-C Cartilage Repair Implant shows promising results in treating knee cartilage defects, outperforming the current surgical standard of care in a recent multicenter randomized controlled trial [1][3][4] Group 1: Product Performance - The CARTIHEAL Implant has received FDA approval and breakthrough designation, indicating its potential to transform the cartilage repair landscape [3][4] - Patients treated with the CARTIHEAL AGILI-C Implant reported significantly better knee pain relief and quality of life improvements over a 4-year period [6] - The implant demonstrated an 87% reduction in the risk of subsequent total knee arthroplasty (TKA) and osteotomy compared to the surgical standard of care, which is a critical consideration for patients with mild to moderate osteoarthritis [4][6] Group 2: Clinical Outcomes - The implant effectively treated a diverse group of patients across various demographics, including age and lesion size, while delivering clinically meaningful results [6] - Professor Elizaveta Kon emphasized the importance of inclusivity in study design, noting that the CARTIHEAL Implant has shown superior performance across genders and lesion locations [4] - The technology is particularly beneficial for patients seeking procedures that allow them to maintain their daily activities, such as playing with children and grandchildren [4] Group 3: Industry Engagement - The CARTIHEAL Implant will be featured at the Arthroscopy Association of North America Annual Meeting (AANA 2025), highlighting its significance in the medical community [1][5] - A lunch symposium will focus on the use of the CARTIHEAL Implant for treating various cartilage pathologies, further promoting its clinical applications [4]

“CORI on Tour” will highlight the latest advancements in robotics-assisted surgery for hip and knee joint replacement Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces a months-long roadshow across central Europe to promote its CORI Surgical System – an advanced robotics-assisted surgical platform for total knee and hip joint replacement procedures. The tour will commence in Berlin today and make dozens of stops at surgical facilities across Germany, Austria and Switzer ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use fundamental analysis and traditional val ...